from Health Care Renewal https://ift.tt/3dZYNWh The Future of Aducanumab - as a Medicine and as a Financial Product - What Happens Now?Healthy Care Renewal
The Future of Aducanumab - as a Medicine and as a Financial Product - What Happens Now?Healthy Care Renewal
To recap: the FDA recently (and foolishly) approved Biogen's monoclonal antibody aducanumab as a treatment for Alzheimer's. It did this on the basis of a surrogate endpoint, amyloid plaque reduction, even though, in NUMEROUS trials, that has not been associated with clinical improvement. The company is claiming that there IS clinical improvement based on high-dose patients in one of two clinical
from Health Care Renewal https://ift.tt/3dZYNWh The Future of Aducanumab - as a Medicine and as a Financial Product - What Happens Now?Healthy Care Renewal
from Health Care Renewal https://ift.tt/3dZYNWh The Future of Aducanumab - as a Medicine and as a Financial Product - What Happens Now?Healthy Care Renewal
0 Response to "The Future of Aducanumab - as a Medicine and as a Financial Product - What Happens Now?Healthy Care Renewal"
Post a Comment